# Important chromosome changes in hematological malignancies
| CML t(9;22), bcr-abl | tyrosine kinase activity |
| --- | --- | 
| ALL t(9;22) t(4;11) | poor prognosis in ALL |

| AML,M2 t(8;21) | good prognosis in AML |

• AML,M3,APL t(15;17) PML-RARα, good prognosis in AML
• AML,M4eo inv(16), good prognosis in AML
• AML, normal cytogenetics (intermediate risk)
Isolated NPM1 or CEBPA mutation: good
FLT3-ITD mutation: poor
• AML 11q23 MLL: poor
• Burkitt’s lymphoma t(8;14) myc oncogene
• Follicular lymphoma t(14;18) bcl-2 (bcl-2: anti-apoptosis)
• Mantle cell lymphoma t(11;14) cyclin D1
